(Q51468797)

English

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

scientific article published on 26 June 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

K Hermansen

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

M Kipnes

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

E Luo

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

D Fanurik

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

H Khatami

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

P Stein

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

Sitagliptin Study 035 Group

7

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

publication date

26 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

9

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

733-745

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2007.00744.X

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17593236

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51468797&oldid=1236915596"